Cynarins

Compound Class	Cynarins — dicaffeoylquinic acids; a subclass of caffeoylquinic (chlorogenic-type) acids
Representative Members	Cynarin (1,3-dicaffeoylquinic acid), chlorogenic acid, and related caffeoylquinic esters
Botanical Sources	Cynara scolymus / Cynara cardunculus (globe artichoke)
Plant Part(s)	Leaf (not the edible flower bud)
Typical Standardisation	Cynarin by HPLC; 2.5–5% common commercial range. Often co-specified with chlorogenic acid
Primary Applications	Digestive/dyspepsia support, choleretic (bile-stimulating) formulation, lipid-metabolism support
Claim Strength (Overview)	Moderate for functional dyspepsia; Moderate but modest-magnitude for cholesterol reduction
Buy from Herbuno	Cynarins 5% Powder (Artichoke Extract) | Standardized Cynara scolymus → Cynarins 2.5% Powder (Artichoke Extract) | Standardized Cynara scolymus L. →

Name origin: Cynarin takes its name from the genus Cynara, itself derived from the Greek kyon (dog), a reference to the dog-tooth-like appearance of the artichoke bract spines. Chemically, cynarin is 1,3-dicaffeoylquinic acid — two caffeic acid units esterified to a quinic acid core — placing it structurally within the same caffeoylquinic family as chlorogenic acid, which co-occurs in the same extract. Traditional use: Artichoke leaf, rather than the edible bud, has been used in European herbal medicine since antiquity as a bitter digestive tonic and liver-supportive remedy, with the intensely bitter leaf decoction employed specifically for indigestion, sluggish digestion of fatty meals, and complaints attributed to poor bile flow — a traditional indication that modern choleretic (bile-stimulating) pharmacology has since substantially vindicated. Artichoke leaf extracts remain in regulated use in Germany and Switzerland as remedies for indigestion. Research trajectory: Artichoke leaf research has advanced along two parallel tracks: a digestive/dyspepsia track building on the traditional bitter-tonic indication and grounded in choleretic mechanism, and a lipid-lowering track that emerged later and has produced consistent but modest effect sizes. Cochrane review of the cholesterol indication has been cautious, noting positive findings across the qualifying trials but describing the overall evidence base as limited by data paucity. Commercial source: Artichoke leaf extract standardized to cynarin content by HPLC is the commercial format, with chlorogenic acid frequently co-specified; the leaf is an agricultural by-product of artichoke cultivation.

---

Evidence for Cynarins Applications

Artichoke leaf extract has a genuine randomized controlled trial supporting its cholesterol-lowering application. A randomized, double-blind, placebo-controlled trial in otherwise healthy adults with mild-to-moderate hypercholesterolemia randomized 75 volunteers to 1,280 mg/day of standardized artichoke leaf extract or matched placebo for twelve weeks, finding an average 4.2% decrease in plasma total cholesterol in the treatment group (Bundy 2008 Phytomedicine). A 4.2% total-cholesterol reduction is real but modest — considerably smaller than statin-class effects — and formulators should size claims to match rather than implying pharmaceutical-scale lipid modification. Claim strength: Moderate.

The digestive/dyspepsia indication, which more closely tracks the traditional use, is supported by a randomized double-blind placebo-controlled multicentre trial in 126 functional dyspepsia patients using a ginger-and-artichoke combination, which found significant symptomatic improvement in the supplemented group, with specific advantages observed for nausea, epigastric fullness, epigastric pain, and bloating (Giacosa 2015). An important caveat for claim scoping: this was a combination product, meaning the trial cannot isolate artichoke’s independent contribution from ginger’s well-documented antiemetic and gastric-motility effects. Claim strength: Moderate.

The proposed mechanism for both indications converges on artichoke’s choleretic activity — stimulation of bile production and flow from the liver. Increased bile secretion plausibly explains both the digestive benefit (bile is essential for fat emulsification, and impaired flow is a recognised contributor to fatty-meal dyspepsia) and, at least partly, the cholesterol effect (bile acid synthesis consumes hepatic cholesterol, and increased bile excretion draws down the cholesterol pool). Additional proposed lipid mechanisms include HMG-CoA reductase modulation attributed to the extract’s luteolin content. Claim strength: Moderate (mechanistic).

A significant compositional caveat for anyone building a claim specifically around cynarin: the pharmacologically active fraction of artichoke leaf extract is a mixture, not a single compound. The key constituents comprise caffeoylquinic acids (cynarin and chlorogenic acid), flavonoids (notably luteolin and its glycosides), and sesquiterpene lactone bitters (including cynaropicrin). Several proposed mechanisms are attributed to luteolin rather than to cynarin specifically, meaning a cynarin percentage should be treated as a standardization marker for the whole extract rather than as the sole active-compound specification. Claim strength: Moderate.

Beyond lipids and dyspepsia, artichoke leaf extract has been evaluated in hepatic contexts, with a randomized double-blind trial in nonalcoholic steatohepatitis patients reporting improvement in liver enzymes alongside reductions in triglycerides and cholesterol versus placebo. This hepatoprotective application aligns mechanistically with the choleretic and traditional liver-tonic profile but rests on a smaller evidence base than the two primary indications above, and warrants correspondingly conservative claim scoping. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries artichoke leaf extract standardized to 5% and 2.5% cynarins by HPLC, alongside a chlorogenic-acid-standardized artichoke extract (5%) for formulators whose claim rests on that constituent specifically, and an unstandardized artichoke leaf extract powder. The availability of both cynarin- and chlorogenic-acid-standardized grades from the same botanical is useful given that both caffeoylquinic constituents are pharmacologically relevant.

Clinical trial dosing for the cholesterol indication has centred on approximately 1,280 mg/day of standardized artichoke leaf extract over twelve weeks, while dyspepsia trials have used varied doses including 640 mg three times daily in one of the larger studies, and hepatic trials have used higher doses (around 2,700 mg/day). Formulators should calculate serving size against the specific extract’s cynarin percentage and be explicit that most trials used whole standardized extract rather than isolated cynarin.

Analytical verification should specify cynarin content by HPLC and, given the multi-constituent nature of the active fraction, ideally include chlorogenic acid and luteolin figures as well. Because several proposed mechanisms are attributed to luteolin rather than the caffeoylquinic acids, an extract standardized solely on cynarin without characterizing its flavonoid content may not fully reproduce the composition of the material used in the supporting clinical trials.

Artichoke leaf extract is generally well tolerated, with mild gastrointestinal effects (flatulence, mild cramping) being the most commonly reported adverse events across the clinical literature. Because the extract is choleretic — it actively stimulates bile flow — standard caution is appropriate for individuals with bile duct obstruction or gallstones, in whom increased bile flow could be problematic, and this warrants explicit label disclosure. Artichoke belongs to the Asteraceae (daisy) family, so cross-sensitivity caution for individuals with known Asteraceae allergy is also appropriate.

---

Frequently Asked Questions — Cynarins

What exactly is cynarin?
Cynarin is 1,3-dicaffeoylquinic acid — two caffeic acid units attached to a quinic acid core. It belongs to the same caffeoylquinic acid family as chlorogenic acid, which co-occurs in artichoke leaf extract. Cynarin is used as the standardization marker for artichoke leaf, though it is not the extract's sole active constituent.

How much does artichoke leaf extract actually lower cholesterol?
A randomized, placebo-controlled trial in adults with mild-to-moderate hypercholesterolemia found an average 4.2% reduction in total plasma cholesterol over twelve weeks at 1,280 mg/day. This is a real but modest effect, substantially smaller than statin-class medications, and claims should be sized accordingly.

Why should people with gallstones be cautious with artichoke extract?
Artichoke leaf extract is choleretic, meaning it actively stimulates bile production and flow. In individuals with bile duct obstruction or gallstones, increased bile flow could be problematic, so caution and label disclosure are appropriate for these populations.

Is cynarin the only active compound in artichoke leaf?
No. The active fraction is a mixture including caffeoylquinic acids (cynarin, chlorogenic acid), flavonoids (particularly luteolin and its glycosides), and sesquiterpene lactone bitters such as cynaropicrin. Several proposed mechanisms are attributed to luteolin rather than cynarin, so the cynarin figure is best treated as a standardization marker for the whole extract.

Related compounds: Chlorogenic Acid, Luteolin, Caffeic Acid, Silybin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery